» Articles » PMID: 31862556

Changes in Fentanyl Demand Following Naltrexone, Morphine, and Buprenorphine in Male Rats

Overview
Publisher Elsevier
Specialty Psychiatry
Date 2019 Dec 22
PMID 31862556
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Individuals with opioid use disorder (OUD) exhibit high levels of economic demand for opioids, with high levels of consumption and relative insensitivity to changes in price. Because the medications used to treat OUD in medication-assisted therapy (MAT) act as antagonists or agonists at μ opioid receptors, they may alter the relationship between price and opioid intake.

Methods: This study examined demand for a commonly abused synthetic prescription opioid, fentanyl, in male rats following s.c. pre-treatment with naltrexone (0.1-1.0 mg/kg), morphine (0.3-3.0 mg/kg) or buprenorphine (0.3-3.0 mg/kg). We normalized demand curves to intake at the lowest price and estimated effects on elasticity (sensitivity to changes in price). Rats were first trained to earn fentanyl (5 μg/kg/infusion) on a fixed ratio schedule, then they underwent daily training under a threshold procedure designed to produce within-session demand curve estimates. Rats received 14 threshold sessions before undergoing a series of tests encompassing each drug, at each dose.

Results: Elasticity was increased by pretreatment with naltrexone, morphine or buprenorphine. Morphine also decreased initial intake, when the price for fentanyl was lowest. In contrast, initial intake was increased by naltrexone (according to an inverted-U shaped curve). The effects of naltrexone did not persist after the test session, but morphine and buprenorphine continued affecting demand elasticity 24 h or 48 h after the test, respectively.

Conclusions: These results indicate that fentanyl demand is sensitive to blockade or activation of opioid receptors by the drug classes used for MAT in humans.

Citing Articles

Escalation of intravenous fentanyl self-administration and assessment of withdrawal behavior in male and female mice.

Chen Y, Xiao T, Kimbrough A Psychopharmacology (Berl). 2024; .

PMID: 39730840 DOI: 10.1007/s00213-024-06739-x.


Enhancing translation: A need to leverage complex preclinical models of addictive drugs to accelerate substance use treatment options.

Corley C, Craig A, Sadek S, Marusich J, Chehimi S, White A Pharmacol Biochem Behav. 2024; 243():173836.

PMID: 39067531 PMC: 11344688. DOI: 10.1016/j.pbb.2024.173836.


Reinforcing effects of fentanyl analogs found in illicit drug markets.

Maitland A, McGriff S, Glatfelter G, Schindler C, Baumann M Psychopharmacology (Berl). 2024; 241(11):2375-2383.

PMID: 38965085 PMC: 11513704. DOI: 10.1007/s00213-024-06641-6.


Fentanyl dysregulates neuroinflammation and disrupts blood-brain barrier integrity in HIV-1 Tat transgenic mice.

Rademeyer K, Nass S, Jones A, Ohene-Nyako M, Hauser K, McRae M J Neurovirol. 2024; 30(1):1-21.

PMID: 38280928 PMC: 11232468. DOI: 10.1007/s13365-023-01186-4.


Impacts of xylazine on fentanyl demand, body weight, and acute withdrawal in rats: A comparison to lofexidine.

Sadek S, Khatri S, Kipp Z, Dunn K, Beckmann J, Stoops W Neuropharmacology. 2023; 245:109816.

PMID: 38128606 PMC: 10843705. DOI: 10.1016/j.neuropharm.2023.109816.


References
1.
Browne R, Segal D . Behavioral activating effects of opiates and opioid peptides. Biol Psychiatry. 1980; 15(1):77-86. View

2.
Murphy J, MacKillop J, Skidmore J, Pederson A . Reliability and validity of a demand curve measure of alcohol reinforcement. Exp Clin Psychopharmacol. 2009; 17(6):396-404. DOI: 10.1037/a0017684. View

3.
Azzam A, McDonald J, Lambert D . Hot topics in opioid pharmacology: mixed and biased opioids. Br J Anaesth. 2019; 122(6):e136-e145. DOI: 10.1016/j.bja.2019.03.006. View

4.
Moerke M, Negus S . Role of agonist efficacy in exposure-induced enhancement of mu opioid reward in rats. Neuropharmacology. 2019; 151:180-188. PMC: 6500752. DOI: 10.1016/j.neuropharm.2019.03.020. View

5.
Porter-Stransky K, Bentzley B, Aston-Jones G . Individual differences in orexin-I receptor modulation of motivation for the opioid remifentanil. Addict Biol. 2015; 22(2):303-317. PMC: 4879120. DOI: 10.1111/adb.12323. View